RESEARCH
Research Grants
In the world of pulmonary hypertension, the word "research" is filled with hope, potential, and excitement. It holds the key to a better understanding of the illness, leading to the development of novel therapies, robust treatments, and more sophisticated tools to care for patients. Research also holds the promise of a better and longer life, better management of symptoms, and ultimately a cure.
Wilma Shastry Pulmonary Arterial Hypertension Research Awards
The Wilma Shastry Pulmonary Arterial Hypertension Research Awards support innovative research aimed at advancing the diagnosis, treatment, and understanding of pulmonary arterial hypertension (PAH). Offered by PHA Canada in partnership with the Canadian Lung Association (CLA), the awards help strengthen Canadian research capacity and encourage new discoveries with the potential to benefit people living with PAH.
The awards provide catalyst funding for new and innovative research projects, including pilot, feasibility, and translational studies. Projects may explore PAH diagnosis, treatment, biology, mechanisms of disease, and respiratory health. Catalyst grants are designed to support promising ideas at an early stage, helping researchers generate the preliminary findings needed to move their work forward.
While the long-term goals of a research project may extend beyond the award period, the funding is intended to create a foundation for future research. Findings from these projects can help researchers develop larger funding proposals for submission to national or international peer-reviewed competitions.
The Wilma Shastry PAH Research Awards are one-year, $40,000 catalyst grants supporting innovative research related to the diagnosis, treatment, and mechanisms of pulmonary arterial hypertension (PAH). The awards are made possible primarily through generous donor contributions supporting respiratory and PAH research.
